Women at risk for gonorrhea: Comparison of rosaramicin and ampicillin plus probenecid in the eradication of neisseria gonorrhoeae, chlamydia trachomatis and genital mycoplasmas

Byron E. Batteiger, Beth E.Walters Zwickl, Morris L.V. French, Robert B. Jones

Research output: Contribution to journalArticle

Abstract

Rosaramicin is a macrolide antibiotic with activity against Neisseria gonorrhoeae, Chlamydia trachomatis, and the genital mycoplasmas Ureaplasma urealyticum and Mycoplasma hom­inis. Its efficacy in the treatment of genital infections was evaluated and compared with that of single-dose ampicillin plus probenicid in women with known, or suspected, uncom­plicated gonococcal infection. Isolation rates for N. gonorrhoeae, C. trachomatis, U. urealyticum, and M. hominis were 72%, 44%, 95%, and 65%, respectively. Rosaramicin cured 24 (89%) of 27 gonococcal infections and 11 (92%) of 12 chlamydial infections. It transiently reduced the carriage of U. urealyticum but had little effect on carriage of M. hominis. Rosaramicin may be of value in the treatment of concurrent gonococcal and chlamydial infections when tetracycline is contraindicated.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalSexually transmitted diseases
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Women at risk for gonorrhea: Comparison of rosaramicin and ampicillin plus probenecid in the eradication of neisseria gonorrhoeae, chlamydia trachomatis and genital mycoplasmas'. Together they form a unique fingerprint.

  • Cite this